Skin diseases

In the therapeutic field of skin diseases, the G-BA has assessed 26 medicinal products in 49 individual procedures. Weighted according to the respective patient share in the resolution, a major additional benefit has been shown for 0% of the subpopulations. A considerable additional benefit has been demonstrated for 13.2% with a minor additional benefit in relation to the comparative treatment for 8.6%%. A non-quantifiable additional benefit has been proved for 11.1% of the subpopulations. For 67.1% of the subpopulations as weighted by resolution shares, no additional benefit was proved, corresponding to 84% of the theoretical maximum population of 8.34 million patients.